Nov 25, 2020

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 1: Integration of PARP-Inhibitor Maintenance Therapy into the Management of Newly Diagnosed Ovarian Cancer — Dr Westin.

CME information and select...

Nov 25, 2020

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 2: Genetic Testing in Ovarian Cancer and Biologic Basis for the Use of PARP Inhibitors — Dr Mirza.

CME information and select publications

Nov 25, 2020

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 3: Biologic Rationale for and Available Data with PARP Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents in the Management of Advanced Ovarian Cancer — Dr Moore.

CME information and select...

Nov 24, 2020

Featuring a discussion on recent data with CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer with Prof Stephen Johnston, including the following topics:

• Management of Localized ER-Positive, HER2-Negative Early Breast Cancer: Recent Advances in Adjuvant Systemic Endocrine-Based Therapies — Stephen...

Nov 23, 2020

Featuring a roundtable discussion with Drs Scott Kopetz, Wells A Messersmith and Alan P Venook on the following topics:

• Biomarkers in Metastatic Colorectal Cancer (mCRC)
• • Case: A man in his mid-20s with microsatellite instability (MSI)-high metastatic adenocarcinoma of the colon and ROS1 deletion experiences a...